• Markets
  • icon
  • Companies
UBI · ASX

Universal Biosensors, Inc. Shs Chess Depository Interests US Prohibited repr 1 sh (ASX:UBI)

AU$0.25

 0.0 (0.0%)
ASX:Live
01/12/2023 04:10:47 PM
HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Target Price
Deviation
Unlock Full Consensus Insights

UBI Overview

UBI Health Scores

Short Term

Mean Revision

Trend

Event

Halo Model

MQV

GARP

MQV Small

Valuation

Value

Consensus

Momentum

Price

Earnings

Growth

Earnings

Dividends

Quality

Capital Efficiency

Balance Sheet

About UBI

Telephone

Address

Description

Universal Biosensors, Inc. engages in the research, development and manufacture of medical diagnostics test systems for point-of-care professional and home use. Its products include blood glucose monitoring, coagulation testing, immunoassay, and molecular diagnostics. The company was founded in 2001 and is headquartered in Rowville, Australia.

UBI Price Chart

Key Stats

Market Cap

AU$50.97M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.17 - 0.34

Trade Value (12mth)

US$4,467.00

1 week

4.17%

1 month

2.04%

YTD

6.38%

1 year

8.7%

All time high

2.2

Key Fundamentals

EPS 3 yr Growth

393.900%

EBITDA Margin

-466.20%

Operating Cashflow

-$10m

Free Cash Flow Return

-49.50%

ROIC

-90.40%

Interest Coverage

-97.00

Quick Ratio

2.60

Other Data

Shares on Issue (Fully Dilluted)

212m

HALO Sector

Next Company Report Date

23-Feb-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

USD

Short Sell (% of issue)

0.00

UBI Announcements

Latest Announcements

Date Announcements

31 October 23

Universal Biosensors to host investor webinar and Q&A

×

Universal Biosensors to host investor webinar and Q&A

31 October 22

Change of Registry Address

×

Change of Registry Address

31 May 22

Form 604 - Jencay Capital Pty ltd

×

Form 604 - Jencay Capital Pty ltd

31 March 09

Annual Report on SEC Form 10-K

×

Annual Report on SEC Form 10-K

31 March 08

Form 10-K Annual Report

×

Form 10-K Annual Report

31 July 23

Appendix 4D and Half Year Results - 30 June 2023

×

Appendix 4D and Half Year Results - 30 June 2023

31 July 23

Half Year Results Presentation - 30 June 2023

×

Half Year Results Presentation - 30 June 2023

31 August 23

Approval and first order for Xprecia Prime in India

×

Approval and first order for Xprecia Prime in India

30 October 23

September 2023 Quarterly Activity Report and Appendix 4C

×

September 2023 Quarterly Activity Report and Appendix 4C

30 October 23

Q3 2023 Results

×

Q3 2023 Results

30 October 23

Q3 2023 Results Presentation - 30 September 2023

×

Q3 2023 Results Presentation - 30 September 2023

30 October 14

Q3 2014 Results Presentation

×

Q3 2014 Results Presentation

30 March 07

Annual Financial Statements

×

Annual Financial Statements

30 June 22

Notification of cessation of securities - UBI

×

Notification of cessation of securities - UBI

30 January 23

UBI launches new product - Fructose Test for Sentia

×

UBI launches new product - Fructose Test for Sentia

29 October 15

Investor Presentation Q3 2015 Results Update

×

Investor Presentation Q3 2015 Results Update

29 March 11

Annual Report

×

Annual Report

29 July 22

New distribution deals in Europe and Glucose Test launch

×

New distribution deals in Europe and Glucose Test launch

29 April 22

Update to Placement Timetable

×

Update to Placement Timetable

29 April 22

Retail Entitlement Offer Booklet

×

Retail Entitlement Offer Booklet

29 April 22

Appendix 2A

×

Appendix 2A

29 April 22

Notice of Meeting/Proxy Statement

×

Notice of Meeting/Proxy Statement

29 April 22

March 2022 Quarterly Activity Report and Appendix 4C

×

March 2022 Quarterly Activity Report and Appendix 4C

29 April 22

Q1 2022 Results

×

Q1 2022 Results

28 March 12

Investor Presentation

×

Investor Presentation

28 July 23

June 2023 Quarterly Activity Report and Appendix 4C

×

June 2023 Quarterly Activity Report and Appendix 4C

28 July 22

June 2022 Quarterly Activity Report & Appendix 4C

×

June 2022 Quarterly Activity Report & Appendix 4C

28 January 22

December 2021 Appendix 4C and Quarterly Activity Report

×

December 2021 Appendix 4C and Quarterly Activity Report

UBI Fundamentals

Per Share Records

Historical data

Forecasted data

USD 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.03 -0.04 -0.09 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.03 -0.04 -0.09 Lock Lock Lock
     Growth % Lock Lock Lock Lock -55.9 -49.9 -111.2 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.02 -0.04 -0.04 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.03 -0.04 -0.06 Lock Lock Lock
     Growth % Lock Lock Lock Lock 22.3 -97.1 -14.1 Lock Lock Lock
     Yield % Lock Lock Lock Lock -11.2 -6.0 -36.4 Lock Lock Lock
DPS $ Lock Lock Lock Lock N/A N/A 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.17 0.11 0.08 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.10 0.06 0.08 Lock Lock Lock
     Growth % Lock Lock Lock Lock -11.7 -40.8 37.2 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 178 178 199 Lock Lock Lock
Basic m Lock Lock Lock Lock 178 178 199 Lock Lock Lock

Financial Records

Historical data

Forecasted data

USD 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Income Statement
Sales $m Lock Lock Lock Lock 2 4 3 Lock Lock Lock
     Growth % Lock Lock Lock Lock -54.0 96.8 -27.6 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 8 11 16 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -1 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -173.3 95.2 -564.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock -50.1 -1.2 -11.3 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 150 101 111 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -7 -9 -15 Lock Lock Lock
     Growth % Lock Lock Lock Lock -12.8 -34.3 -56.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock -316.2 -215.9 -466.2 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 2 2 2 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -9 -11 -17 Lock Lock Lock
     Growth % Lock Lock Lock Lock -19.5 -30.6 -46.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock -392.1 -260.3 -527.7 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -7 -11 -24 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -2 -3 -5 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -5 -8 -19 Lock Lock Lock
     Growth % Lock Lock Lock Lock -56.0 -50.1 -136.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock -238.5 -181.9 -593.5 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -6 -7 -10 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 1 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 -1 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 0 0 17 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -6 -8 -11 Lock Lock Lock
     Growth % Lock Lock Lock Lock -126.0 -32.8 -42.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock -2.7 -1.8 -3.6 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 20 13 18 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 44 32 31 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 3 1 3 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -17 -11 -15 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 15 12 14 Lock Lock Lock
Equity $m Lock Lock Lock Lock 26 21 18 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 32 21 20 Lock Lock Lock
     Growth % Lock Lock Lock Lock 0.8 -33.8 -3.8 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -11.9 -24.3 -59.3 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -20.1 -38.1 -102.9 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -28.7 -41.8 -78.6 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -17.6 -29.6 -90.4 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -19.1 -27.9 -49.5 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

USD 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Leverage
Interest Cover X Lock Lock Lock Lock -65.4 -102.3 -97.0 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 2.4 1.2 1.0 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -63.7 -52.6 -81.4 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 3.5 2.6 2.8 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 3.3 2.4 2.6 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 82.0 69.6 72.3 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -82.5 -108.9 -114.7 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 33.8 21.0 1.5 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 3.2 2.9 1.9 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.1 0.4 0.2 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 14.0 7.6 5.9 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.1 0.1 0.1 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.1 0.1 0.1 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -326.7 -249.3 -766.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -16.3 -33.4 -76.6 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -11.9 -24.3 -59.3 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.7 1.6 1.7 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -20.1 -38.1 -102.9 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock N/A N/A 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock N/A N/A -102.9 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 112.3 125.5 191.6 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 10.8 17.3 249.5 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 123.1 142.9 441.1 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 34.6 26.4 21.3 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 88.5 116.5 419.8 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

UBI Shortsell

Frequently Asked Questions

The current share price of Universal Biosensors, Inc. Shs Chess Depository Interests US Prohibited repr 1 sh (UBI:ASX) is AU$0.25.
The 52-week high share price for Universal Biosensors, Inc. Shs Chess Depository Interests US Prohibited repr 1 sh (UBI:ASX) is AU$0.34.
The 52-week low share price for Universal Biosensors, Inc. Shs Chess Depository Interests US Prohibited repr 1 sh (UBI:ASX)? is AU$0.17.
Universal Biosensors, Inc. Shs Chess Depository Interests US Prohibited repr 1 sh (UBI:ASX) does not pay a dividend.
Universal Biosensors, Inc. Shs Chess Depository Interests US Prohibited repr 1 sh (UBI:ASX) does not pay a dividend.
Universal Biosensors, Inc. Shs Chess Depository Interests US Prohibited repr 1 sh (UBI:ASX) has a franking level of 0%.
Universal Biosensors, Inc. Shs Chess Depository Interests US Prohibited repr 1 sh (UBI:ASX) is classified in the Healthcare.
The current P/E ratio for Universal Biosensors, Inc. Shs Chess Depository Interests US Prohibited repr 1 sh (UBI:ASX) is .